MH3: VALIDATION OF A METHODOLOGY FOR ESTIMATING PRODUCTIVITY GAINS FROM IMPROVEMENTS IN HAM-D SCORES  by Schonfeld, WH & Sheriff, SK
308 Abstracts
for insulin or an oral hypoglycemic agent) before begin-
ning anti-psychotic therapy were excluded. New diabetes
diagnoses after the first antipsychotic prescription were
tabulated until 31st December 1999; censoring occurred
at this date, or the diagnosis of diabetes or at the last ser-
vice date if there was no record of using any services dur-
ing the last six months. Crude hazard ratios and propor-
tional hazards analyses were carried out. RESULTS: 336
patients developed diabetes after being prescribed olanza-
pine, and 220 after risperidone, a crude hazard ratio of
1.10 (95% CI 0.90 to 1.35). When correcting for severe
imbalances in age and gender using proportional hazards
analysis, the hazard ratio increased to 1.22 (95% CI 1.02
to 1.45). After also adjusting for the duration of olanza-
pine exposure, the first three months of olanzapine treat-
ment was associated with the highest risk of diabetes,
hazard ratio 1.91 (95% CI 1.42 to 2.58). CONCLU-
SIONS: Olanzapine was associated with an increased risk
of developing diabetes compared to risperidone. More
studies are required to confirm the association of olanza-
pine with hyperglycemia and to identify the patient
groups at highest risk of developing diabetes.
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Major costs associated with depression are related to
work loss and reduced productivity. Since treatment can
improve functioning in these areas, economic evaluations
of new antidepressants should consider their impact on
productivity costs. However, clinical trials do not gener-
ally measure effects of pharmacotherapy on disability
days but rather use patient or clinician assessments of
functioning (e.g., HAM-D). We have developed (and pre-
viously reported) a method using HAM-D scores to esti-
mate disability days for comparing economic impact of
different treatments. OBJECTIVES: The methodology is
based upon theoretical considerations. In order to strengthen
its value for practical applications, the current study as-
sesses the predictive validity of the proposed methodol-
ogy. METHODS: As patients using antidepressants make
clinical improvements, the methodology predicts associ-
ated gains in productivity. We compared the gains pre-
dicted for clinical trial patients to actual observations
from a real-world setting. For this purpose, we used data
reported by Treglia and Neslusan at ISPOR’s 5th annual
international meeting, and derived from a commercial
health care database, examining patterns of absenteeism
for 716 employees newly diagnosed with depression from
1994–1996. RESULTS: The observed number of medical
absences averaged 14.0 days during the first 2 months af-
ter pharmacotherapy began and 7.5 during the next 2
months. In comparison, our new methodology predicted
12.4 days during the 2 months of initial treatment and
5.2 days in the following 2-month period. CONCLU-
SIONS: The new methodology predicted similar absen-
teeism for clinical trial patients as that observed among
employees. The different levels of absenteeism are likely
due to differences between the two groups (i.e., clinical
trial versus real world). Since our results support the pre-
dictive validity of the methodology, we are proceeding to
use it conditional upon further validation involving si-
multaneous measurement of both HAM-D scores and
disability days in a sample of patients with depression.
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OBJECTIVE: To assess patient quality-of-life and utili-
ties for health states associated with different levels of
amyotrophic lateral sclerosis (ALS) severity. METHODS:
A structured interview was conducted with 77 patients,
in 2 UK centers, covering four different clinical stages of
ALS severity. Patients completed a disease specific health
status measure (ALSAQ-40), a generic health status mea-
sure (EuroQol EQ-5D), visual analog scale (VAS) rating
of current health and a standard gamble (SG) exercise to
provide health state utilities for their own health state.
RESULTS: The ALSAQ-40 was sensitive to disease sever-
ity, with scores for later stage disease states showing a
lower level of patient rated health status than the scores
for early stage disease states. Patients’ mean VAS rating
of their own health ranged from 0.74 (95% CI: 0.64–
0.85) for stage 1 (early) disease severity (n  15), to 0.37
(95% CI: 0.29–0.46) for stage 4 (late stage) disease sever-
ity (n  19). The mean VAS rating for the entire group
was 0.55 (95% CI: 0.50–0.60), (n  76). Utilities elicited
via SG were systematically higher than VAS scores and
ranged from a mean of 0.79 (95% CI: 0.71–0.88) for
stage 1 disease severity (n  15) to a mean of 0.45 (95%
CI: 0.28–0.61) for stage 4 disease severity (n  19). The
mean SG score for the entire group was 0.65 (95% CI:
0.58–0.71), (n  76). The EQ-5D was not sensitive to the
different levels of disease severity. CONCLUSIONS: This
study demonstrates that it is feasible and practical to ob-
tain ALS patients’ valuations of their current health state.
VAS and SG values associated with each of the 4 stages
of disease severity fell as disease severity progressed
through stages 1 to 4. ALS patients’ rating of their health
state and the SG scores provide evidence that patients
value their health-related quality-of-life highly, even in
cases where health status is very poor.
